EUVIMEDEUVIMED entdecken
Crossref

Fibroblast transcriptomics uncovers pathogenic genomic variants in individuals with exome‐negative childhood onset epilepsy

Noor Smal, Charissa Millevert, Matthias De Wachter iD, Els De Vriendt, Zakaria Eddafir iD, An-Sofie Schoonjans iD, Allan Bayat iD, Rikke Steensbjerre Møller iD, Davide Mei iD, Simona Balestrini, Renzo Guerrini, Marije E C Meeuwissen und 2 weitere

Epilepsia · 2025

DOI: 10.1111/epi.18279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Noor Smal und 13 weiteren Autor:innen. Beteiligte Einrichtung: Applied Translational Neurogenomics Group, Vlaams Instituut voor Biotechnology (VIB) Center for Molecular Neurology, VIB, Antwerp, Belgium. Hauptthemen laut MEDLINE: Fibroblasts, Epilepsy, Transcriptome, Exome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: DECODE-EE Call health 2018, Fondazione CARIFI, Ministero dell'Istruzione, dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to improve genetic diagnosis in childhood onset epilepsy with neurodevelopmental problems by utilizing RNA sequencing of fibroblasts to identify pathogenic variants that may be missed by exome sequencing and copy number variation analysis.

Methods

We enrolled 41 individuals with childhood onset epilepsy and neurodevelopmental problems who previously had inconclusive genetic testing. Fibroblast samples were cultured and analyzed using RNA sequencing to detect aberrant expression, aberrant splicing, and monoallelic expression using the Detection of RNA Outlier Pipeline (DROP) pipeline. Detected events were correlated with phenotypes, and long‐read genome sequencing was performed on individuals with strong candidate events to identify the causal genomic variant. A systematic literature review on RNA sequencing in rare disorders was conducted to contextualize our findings.

Results

RNA sequencing identified five strong candidate events in four individuals, affecting the genes QRICH1 , TSC1 , SMARCA1 , GNAI1 , and PTEN . (Likely) pathogenic genomic variants affecting expression of QRICH1 , TSC1 , and SMARCA1 were detected, resulting in a diagnostic yield of 7% (3/41). Two variants were not covered in the initial exome sequencing data but were revealed through long‐read sequencing. The identification of a pathogenic TSC1 variant led to a previously unrecognized diagnosis of tuberous sclerosis complex. This prompted guideline‐based screening, which revealed tuberous sclerosis lesions in the brain and lung, directly impacting clinical care. Notably, two of the three pathogenic events would not have been detected using whole blood due to the lack of expression of the involved genes. The lower yield of this study compared to studies in other rare disorders reflects the genetic heterogeneity of epilepsy and neurodevelopmental disorders, and the inaccessibility of affected tissue. Significance This research underscores RNA sequencing of cultured fibroblasts as a valuable tool in genetic diagnostics for childhood onset epilepsy, particularly when conventional methods fail. Expanding the control dataset with age‐matched samples and incorporating RNA sequencing with nonsense‐mediated decay inhibition could further enhance diagnostic yield.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibroblastsEpilepsyTranscriptomeExomeHumansChildMaleFemaleChild, PreschoolAdolescentExome SequencingDNA Copy Number VariationsSequence Analysis, RNAGenetic Variation

Stichwörter der Autor:innen

RNA sequencingchildhood epilepsydiagnostics

Autor:innen und Institutionen

  • Applied Translational Neurogenomics Group, Vlaams Instituut voor Biotechnology (VIB) Center for Molecular Neurology, VIB, Antwerp, Belgium.
  • Applied Translational Neurogenomics Group, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.
  • Division of Pediatric Neurology, Department of Pediatrics, Antwerp University Hospital, Antwerp, Belgium.
  • Department of Pediatrics, Danish Epilepsy Center, Dianalund, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Matthias De Wachter, Zakaria Eddafir, An-Sofie Schoonjans, Allan Bayat, Rikke Steensbjerre Møller, Davide Mei, Sarah Weckhuysen

Förderung

  • DECODE-EE Call health 2018
  • Fondazione CARIFI
  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • ricerca finalizzata
  • Current research 2023, Italian ministry of health
  • Geneeskundige Stichting Koningin Elisabeth (G.S.K.E.)
  • Fonds Wetenschappelijk Onderzoek
  • Universiteit Antwerpen

Zitieren

APA

Smal, N., Millevert, C., De Wachter, M., De Vriendt, E., Eddafir, Z., Schoonjans, A. S., Bayat, A., Møller, R. S., Mei, D., Balestrini, S., Guerrini, R., Meeuwissen, M. E. C., Jansen, A. C., & Weckhuysen, S. (2025). Fibroblast transcriptomics uncovers pathogenic genomic variants in individuals with exome‐negative childhood onset epilepsy. Epilepsia. https://doi.org/10.1111/epi.18279

Vancouver

Smal N, Millevert C, De Wachter M, De Vriendt E, Eddafir Z, Schoonjans AS, et al. Fibroblast transcriptomics uncovers pathogenic genomic variants in individuals with exome‐negative childhood onset epilepsy. Epilepsia. 2025. doi:10.1111/epi.18279

BibTeX
@article{Smal2025,
  author = {Smal, Noor and Millevert, Charissa and De Wachter, Matthias and De Vriendt, Els and Eddafir, Zakaria and Schoonjans, An-Sofie and Bayat, Allan and Møller, Rikke Steensbjerre and Mei, Davide and Balestrini, Simona and Guerrini, Renzo and Meeuwissen, Marije E C and Jansen, Anna C and Weckhuysen, Sarah},
  title = {Fibroblast transcriptomics uncovers pathogenic genomic variants in individuals with exome‐negative childhood onset epilepsy},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18279}
}
Kostenlos starten →